EU-PEARL brings together patients, clinicians, industry, researchers and authorities to create an open and trusted environment for knowledge sharing and science-driven debate on innovative clinical trials. Extensive cooperation amongst all stakeholders to improve health outcomes for patients is the driving force behind EU-PEARL.
EU-PEARL promotes a new paradigm of collaborative platform trials, where patients play a bigger part in trial designs and outcomes, whilst they increase their opportunities to gain speedier access to more effective and personalized techniques and treatments. Thus, the ensuing EU-PEARL framework aims to support better health and care for patients.
EU-PEARL will develop a tested and trusted framework to set up and coordinate the operations of multi-company platform trials in any disease area. Once EU-PEARL is completed, sustainable and reusable Integrated Research Platforms (IRPs) will be in place to provide high quality evidence based on strong and consistent data networks and statistical methods.
EU-PEARL brings together patients, clinicians, industry, researchers and health authorities to create an open and trusted environment for knowledge sharing and science-driven debate on innovative clinical trials. Extensive cooperation amongst all stakeholders to improve health outcomes for patients is the driving force behind EU-PEARL.
EU-PEARL promotes a new paradigm of collaborative platform trials, where patients play a bigger part in trial designs and outcomes, whilst they increase their opportunities to gain speedier access to more precise and personalised treatments. Thus, the ensuing EU-PEARL framework will support better health and care for patients.
EU-PEARL will develop a tested and trusted framework to set up and coordinate the operations of cross-company platform trials in any disease area. Once EU-PEARL is completed, sustainable and replicable IRPs will be in place to provide high quality evidence based on strong and consistent data networks and statistical methods.
EU-PEARL is a strategic alliance between the public and private sectors to transform the way clinical trials are conducted. By creating an innovative framework that incorporates patients’ perspectives, EU-PEARL aims to improve and accelerate drug development processes, thus bringing about new and more effective treatments, faster.
Recent developments in scientific research, technological innovation and advance on big data analysis open a new world of opportunities for clinical trials. Based on this new reality, the paradigm of IRPs that EU-PEARL is set to develop, will bring more efficiency to the design and implementation of clinical trials, potentially improving the speed of making new drugs available to patients.
EU-PEARL aims to improve health outcomes for patients by transforming the way clinical trials are conducted. To achieve this highly ambitious goal, the public and private sector have formed this strategic alliance which will lay the foundations for the future of drug development in the EU.
New developments in scientific research and technological innovation open a new world of opportunities for clinical trials. The paradigm of Integrated Research Platforms that EU-PEARL is set to develop, will bring more efficiency to the design and implementation of clinical trials, potentially improving the speed and costs of making new drugs available to patients.
